7 reasons why you should use avanafil in erectile dysfunction Review article
Article Sidebar
Published:
Sep 30, 2016
Keywords:
erectile dysfunction, avanafil, treatment
Main Article Content
Abstract
Currently, erectile dysfunction affects a great number of men. This dysfunction negatively impacts their quality of life and, in many of them, it is the first symptom of impending myocardial infarction. In the treatment of erectile dysfunction, phosphodiesterase-5 (PDE5) inhibitors are the recommended first-line treatment. European Association of Urology Guidelines updated 2015 recommend the use of PDE5 inhibitors, including avanafil, which sets a new standard for safety and efficacy in the treatment of erectile dysfunction due to its unique properties.
Article Details
How to Cite
Kałka, D. (2016). 7 reasons why you should use avanafil in erectile dysfunction. Medycyna Faktow (J EBM), 9(3(32), 231-235. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2226
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
2. Eardley I.: The incidence, prevalence and natural history of erectile dysfunction. Sex. Med. Rev. 2013; 1: 13-16.
3. Kałka D., Domagała Z., Rakowska A. et al.: Modifiable risk factors for erectile dysfunction – an assessment of the awareness of such factors in patients suffering from ischemic heart disease. Int. J. Impot. Res. 2016; 28: 14-19.
4. Aytac I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
5. Hatzimouratidis K., Eardley I., Giuliano F. et al.: Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. The Netherlands: European Association of Urology 2015 .
6. Awanafil. Charakterystyka produktu leczniczego. 2013.
7. Hellstrom W.J., Kaminetsky J., Belkoff L.H. et al.: Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. J. Urol. 2015; 194(2): 485-492.
8. Levine G.N., Steinke E.E., Bakaeen F.G. et al.: Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125(8): 1058-1072.
9. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Goldstein I., Jones L.A., Belkoff L.H. et al.: Avanafil for the treatment of erectile dysfunction: a multicenter randomized double-blind study in men with diabetes mellitus. Mayo Clin. Proc. 2012; 87: 843-852.
11. Mulhall J.P., Burnett A.L., Wang R. et al.: A phase 3, placebo-controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve-sparing radical prostatectomy. J. Urol. 2013; 189: 2229-2236.
12. Montorsi F., Briganti A., Salonia A. et al.: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Eurol. 2003; 44: 360-364.
13. Mullhall J., King R., Glina S. et al.: Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J. Sex. Med. 2008; 5: 788-795.
2. Eardley I.: The incidence, prevalence and natural history of erectile dysfunction. Sex. Med. Rev. 2013; 1: 13-16.
3. Kałka D., Domagała Z., Rakowska A. et al.: Modifiable risk factors for erectile dysfunction – an assessment of the awareness of such factors in patients suffering from ischemic heart disease. Int. J. Impot. Res. 2016; 28: 14-19.
4. Aytac I.A., McKinlay J.B., Krane R.J.: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999; 84: 50-56.
5. Hatzimouratidis K., Eardley I., Giuliano F. et al.: Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. The Netherlands: European Association of Urology 2015 .
6. Awanafil. Charakterystyka produktu leczniczego. 2013.
7. Hellstrom W.J., Kaminetsky J., Belkoff L.H. et al.: Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. J. Urol. 2015; 194(2): 485-492.
8. Levine G.N., Steinke E.E., Bakaeen F.G. et al.: Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125(8): 1058-1072.
9. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34(38): 2949-3003.
10. Goldstein I., Jones L.A., Belkoff L.H. et al.: Avanafil for the treatment of erectile dysfunction: a multicenter randomized double-blind study in men with diabetes mellitus. Mayo Clin. Proc. 2012; 87: 843-852.
11. Mulhall J.P., Burnett A.L., Wang R. et al.: A phase 3, placebo-controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve-sparing radical prostatectomy. J. Urol. 2013; 189: 2229-2236.
12. Montorsi F., Briganti A., Salonia A. et al.: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Eurol. 2003; 44: 360-364.
13. Mullhall J., King R., Glina S. et al.: Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J. Sex. Med. 2008; 5: 788-795.